Takeda licenses microbiome IBD candidate from Finch Therapeutics; terminates partnership
Finch Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. exclusive global rights to develop and sell its microbiome candidate FIN524, which is in preclinical studies for inflammatory bowel disease.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.